Dipeptidyl peptidase 4 (DPP-4) inhibitors

Linagliptin

Approved 30 Mar 2023OralTablet

The FDA lists this product in 8 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: LINAGLIPTIN 5MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA208448.

Open Drugs@FDA

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Linagliptin
Drug class: Dipeptidyl peptidase 4 (DPP-4) inhibitors, Combinations of oral blood glucose lowering drugs
Group: Diabetes medicines
Route: Oral
Dosage form: Tablet
Applicant: Zydus Pharms
Status: Prescription
FDA approval: 30 Mar 2023
Application: ANDA208448-001
RxCUI: 1100699